Andreas Argyrides
Stock Analyst at Oppenheimer
(4.50)
# 270
Out of 5,128 analysts
118
Total ratings
53.92%
Success rate
21.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Upgrades: Outperform | $11 → $40 | $19.39 | +106.29% | 5 | Dec 10, 2025 | |
| SVRA Savara | Maintains: Outperform | $8 → $9 | $5.77 | +55.98% | 2 | Nov 14, 2025 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $23 → $27 | $18.56 | +45.47% | 9 | Nov 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $65.01 | +76.90% | 2 | Oct 2, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $26 → $21 | $3.42 | +514.04% | 2 | Oct 2, 2025 | |
| BNTC Benitec Biopharma | Maintains: Outperform | $35 → $29 | $12.14 | +138.88% | 2 | Sep 16, 2025 | |
| KALA KALA BIO | Maintains: Outperform | $15 → $33 | $0.67 | +4,862.41% | 2 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $510 → $575 | $503.69 | +14.16% | 1 | Sep 5, 2025 | |
| MNKD MannKind | Maintains: Outperform | $12 → $15 | $5.85 | +156.41% | 2 | Sep 5, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Outperform | $19 → $20 | $5.22 | +283.14% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $61 | $37.55 | +62.45% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $6.23 | +12.36% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $1.20 | +150.00% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $13 | $30.99 | -58.05% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $1.39 | +187.77% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $8.49 | +960.07% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $2.16 | +316.67% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $213.28 | -15.14% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $11.29 | +821.17% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $2.41 | +273.44% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $11.10 | +71.17% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $20.97 | +38.29% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $15.24 | +37.80% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $23.46 | +854.82% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $26.00 | +119.23% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.69 | +914.49% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.46 | +2,073.91% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $61.31 | +14.17% | 6 | Aug 1, 2023 |
Dyne Therapeutics
Dec 10, 2025
Upgrades: Outperform
Price Target: $11 → $40
Current: $19.39
Upside: +106.29%
Savara
Nov 14, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $5.77
Upside: +55.98%
Keros Therapeutics
Nov 12, 2025
Reiterates: Outperform
Price Target: $23 → $27
Current: $18.56
Upside: +45.47%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $65.01
Upside: +76.90%
Larimar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $3.42
Upside: +514.04%
Benitec Biopharma
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $12.14
Upside: +138.88%
KALA BIO
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $0.67
Upside: +4,862.41%
United Therapeutics
Sep 5, 2025
Maintains: Outperform
Price Target: $510 → $575
Current: $503.69
Upside: +14.16%
MannKind
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $5.85
Upside: +156.41%
Abeona Therapeutics
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $5.22
Upside: +283.14%
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $37.55
Upside: +62.45%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $6.23
Upside: +12.36%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $1.20
Upside: +150.00%
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $30.99
Upside: -58.05%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $1.39
Upside: +187.77%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $8.49
Upside: +960.07%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $2.16
Upside: +316.67%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $213.28
Upside: -15.14%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $11.29
Upside: +821.17%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $2.41
Upside: +273.44%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $11.10
Upside: +71.17%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $20.97
Upside: +38.29%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $15.24
Upside: +37.80%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $23.46
Upside: +854.82%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $26.00
Upside: +119.23%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.69
Upside: +914.49%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.46
Upside: +2,073.91%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $61.31
Upside: +14.17%